{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Drye LT"],"funding":["NIA NIH HHS","NIMH NIH HHS"],"pagination":["573-83"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC3414254"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["26(6)"],"pubmed_abstract":["<h4>Objective</h4>To determine if the effect of sertraline in the depression in Alzheimer's disease study - 2 (DIADS-2) differed in subgroups of patients defined by baseline depression criteria.<h4>Methods</h4>DIADS-2 was a randomized, parallel, placebo-controlled, multicenter trial designed to evaluate the efficacy and safety of sertraline (target dose of 100 mg/day) for the treatment of depression in patients with Alzheimer's disease. DIADS-2 enrolled 131 patients who met criteria for the depression of Alzheimer's disease (dAD). Analyses reported here examined if the effect of sertraline differed in various subgroups, including those meeting criteria for major depressive episode (MaD), minor depressive episode (MiD), and Alzheimer's-associated affective disorder (AAAD) at baseline.<h4>Re"],"journal":["International journal of geriatric psychiatry"],"pubmed_title":["Do treatment effects vary among differing baseline depression criteria in depression in Alzheimer's disease study ± 2 (DIADS-2)?"],"pmcid":["PMC3414254"],"funding_grant_id":["1U01MH066136","U01 MH066175-05","1U01MH066176","1U01MH068014","1U01MH066177","U01 MH066136","U01 MH066177","U01 MH066176","U01 MH066175","U01 MH066174","U01 MH068014","K08 AG029157","1U01MH066174","1U01MH066175"],"pubmed_authors":["Casper AS","O'Neill K","Zhang J","Faison WE","Frangakis CE","Mosely A","Stump T","Onyike C","Goldstein B","Hatchell M","Longmire C","Martin K","Sanabria R","Rabins P","Munro CA","Lyketsos C","Wang Y","Rosenberg P","Zachariah E","DiFilippo S","Niederehe G","Vaidya V","Drye LT","Morrison A","Stuckey M","Evans J","Evans C","Chisar J","Katz I","Martin BK","Lyketsos CG","Pawluczyk S","Porsteinsson AP","Meinert J","McCallum C","Avramopoulos D","Frangakis C","Weintraub D","Jakimovich L","Cosman K","Meinert C","Rosenberg PB","Porsteinsson A","Dagerman K","Shanklin A","Streim J","Hong M","Ritz L","Rabins PV","Schneider LS","Boehner K","LaFountain J","Meinert CL","Munro C","Schneider L","Martin B","Drye L","Boehmer K","Mintzer J","Mintzer JE","Rastogi P","DIADS-2 Research Group"],"additional_accession":[]},"is_claimable":false,"name":"Do treatment effects vary among differing baseline depression criteria in depression in Alzheimer's disease study ± 2 (DIADS-2)?","description":"<h4>Objective</h4>To determine if the effect of sertraline in the depression in Alzheimer's disease study - 2 (DIADS-2) differed in subgroups of patients defined by baseline depression criteria.<h4>Methods</h4>DIADS-2 was a randomized, parallel, placebo-controlled, multicenter trial designed to evaluate the efficacy and safety of sertraline (target dose of 100 mg/day) for the treatment of depression in patients with Alzheimer's disease. DIADS-2 enrolled 131 patients who met criteria for the depression of Alzheimer's disease (dAD). Analyses reported here examined if the effect of sertraline differed in various subgroups, including those meeting criteria for major depressive episode (MaD), minor depressive episode (MiD), and Alzheimer's-associated affective disorder (AAAD) at baseline.<h4>Re","dates":{"release":"2011-01-01T00:00:00Z","publication":"2011 Jun","modification":"2025-04-22T00:33:52.915Z","creation":"2019-03-26T22:51:48Z"},"accession":"S-EPMC3414254","cross_references":{"pubmed":["20672243"],"doi":["10.1002/gps.2565"]}}